News

FDA approves first generic form of oxiconazole nitrate cream


 

References

A generic formulation of oxiconazole nitrate cream, 1% has been approved by the Food and Drug Administration, for the treatment of tinea pedis, tinea cruris, tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum) and tinea (pityriasis) versicolor due to Malassezia furfur.

This is the first generic version of Oxistat to be approved, according to the FDA’s statement announcing the approval.

The label for the generic, manufactured by Taro Pharmaceuticals U.S.A. is available here.

emechcatie@frontlinemedcom.com

Recommended Reading

Zika vaccine candidates possible by early 2017
MDedge Internal Medicine
When toenail onychomycosis can turn deadly
MDedge Internal Medicine
Severe dengue fever outcomes predicted via metabolomics
MDedge Internal Medicine
Flu activity reaches another new season high
MDedge Internal Medicine
Flu vaccination found safe in surgical patients
MDedge Internal Medicine
Antivirals, pain relief, rest are key to zoster management
MDedge Internal Medicine
As varicella recedes, zoster rises: The question is ‘why?’
MDedge Internal Medicine
Study links microcephaly to first trimester Zika infection
MDedge Internal Medicine
Dengue vaccine 100% effective in human challenge trial
MDedge Internal Medicine
Better control of asymptomatic C. difficile needed in communities
MDedge Internal Medicine